{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:52:55Z","timestamp":1780631575133,"version":"3.54.1"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2007,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            We evaluated two formulations of a new combined\n            <jats:italic>Haemophilus influenzae<\/jats:italic>\n            type b (Hib)-meningococcal serogroup C (MenC)-tetanus toxoid (TT) conjugated vaccine and two formulations of a new MenC-TT vaccine (trials 711202\/001 and 711202\/008; clinical trial register numbers NCT00135486 and NCT00135564 [\n            <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"url\" xlink:href=\"www.ClinicalTrials.gov\">www.ClinicalTrials.gov<\/jats:ext-link>\n            ]). A total of 520 healthy infants were randomized to receive primary vaccination (at 2, 3, and 4 months) with either MenC-TT plus diphtheria-tetanus-acellular pertussis (DTPa)-hepatitis B virus (HBV)-inactivated poliovirus (IPV)\/Hib, Hib-MenC-TT plus DTPa-HBV-IPV, or MenC-CRM\n            <jats:sub>197<\/jats:sub>\n            plus DTPa-HBV-IPV\/Hib (control). At 12 to 15 months, subjects received a polysaccharide challenge with meningococcal polysaccharide C plus a DTPa-HBV-IPV\/Hib booster. Immune responses were assessed 1 month after dose 2, 1 month after dose 3, and prior to and 1 month after the booster. After primary vaccination, there was no difference between groups in seroprotection rates as measured by titers of serum bactericidal antibody (SBA) to MenC (\u22651:8) or concentrations of anti-polyribosyl ribitol phosphate (PRP) antibody (\u22650.15 \u03bcg\/ml). Prior to the booster, there was no difference between groups in SBA seroprotection rates, whereas anti-PRP seroprotection rates were significantly higher after priming with Hib-MenC-TT. Booster doses induced large increases in SBA and anti-PRP antibodies in primed groups, indicating successful priming with induction of immune memory. Reactogenicity and safety were similar in all groups during the primary and booster phases. A novel combined Hib-MenC-TT conjugate vaccine induced MenC and Hib responses comparable to those induced by licensed monovalent vaccines. A Hib-MenC-TT conjugate vaccine provides vaccination against two major pathogens in a single injection and is a suitable candidate for use in primary or booster vaccination schedules.\n          <\/jats:p>","DOI":"10.1128\/cvi.00377-06","type":"journal-article","created":{"date-parts":[[2007,2,8]],"date-time":"2007-02-08T01:29:01Z","timestamp":1170898141000},"page":"426-434","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":40,"title":["Immunogenicity, Reactogenicity, and Immune Memory after Primary Vaccination with a Novel\n            <i>Haemophilus influenzae<\/i>\n            -\n            <i>Neisseria meningitidis<\/i>\n            Serogroup C Conjugate Vaccine"],"prefix":"10.1128","volume":"14","author":[{"given":"Heinz-J.","family":"Schmitt","sequence":"first","affiliation":[{"name":"Johannes-Gutenberg-Universita\u0308t, Langenbeckstr. 1, 55101 Mainz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Maechler","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirmin","family":"Habermehl","sequence":"additional","affiliation":[{"name":"Johannes-Gutenberg-Universita\u0308t, Langenbeckstr. 1, 55101 Mainz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Knuf","sequence":"additional","affiliation":[{"name":"Johannes-Gutenberg-Universita\u0308t, Langenbeckstr. 1, 55101 Mainz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Saenger","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Begg","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Boutriau","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"1143","year":"1998","unstructured":"Anderson, M. S., M. P. Glod\u00e9, and A. L. Smith. 1998. Meningococcal disease, p. 1143-1156. In R. D. Feigin and J. D. Cherry (ed.), Textbook of pediatric infectious diseases. W. B. Saunders Company, Philadelphia, PA.","journal-title":"Textbook of pediatric infectious diseases"},{"key":"e_1_3_2_3_2","first-page":"780","volume":"10","year":"2003","unstructured":"Andrews, N., R. Borrow, and E. Miller. 2003. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol.10:780-786.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1016\/S0264-410X(03)00420-1","volume":"21","year":"2003","unstructured":"Ar\u00edstegui, J., R. Dal-R\u00e9, J. D\u00edez-Delgado, J. Mares, J. M. Casanovas, P. Garcia-Corbeira, E. De Frutos, D. Van Esso, J. Verdaguer, J. De la Flor, F. Moraga, R. Boceta, and J. A. Garcia-Martinez. 2003. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV\/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine21:3593-3600.","journal-title":"Vaccine"},{"key":"e_1_3_2_5_2","first-page":"407","volume":"26","year":"2002","unstructured":"Australian Meningococcal Surveillance Programme. 2002. Annual report of the Australian Meningococcal Surveillance Programme, 2001. Commun. Dis. Intell.26:407-418.","journal-title":"Commun. Dis. Intell."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(05)66270-8","volume":"350","year":"1997","unstructured":"B\u00f6hm, O., and R. von Kries. 1997. Are Hib boosters redundant? Lancet350:67.","journal-title":"Lancet"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.10.5549-5555.2003"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(02)08416-7","volume":"359","year":"2002","unstructured":"Jodar, L., I. M. Feavers, D. Salisbury, and D. M. Granoff. 2002. Development of vaccines against meningococcal disease. Lancet359:1499-1508.","journal-title":"Lancet"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/adc.2005.076109","volume":"92","year":"2007","unstructured":"Kitchin, N. R., J. Southern, R. Morris, F. Hemme, S. Thomas, M. W. Watson, K. Cartwright, and E. Miller. 2007. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch. Dis. Child.92:11-16.","journal-title":"Arch. Dis. Child."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.4.2.156-167.1997"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","volume":"20","year":"2001","unstructured":"Miller, E., D. Salisbury, and M. Ramsay. 2001. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine20:S58-S67.","journal-title":"Vaccine"},{"key":"e_1_3_2_12_2","unstructured":"Netherlands Reference Laboratory for Bacterial Meningitis. 2003. Bacterial meningitis in The Netherlands: annual report. Netherlands Reference Laboratory for Bacterial Meningitis Academic Medical Center of the University of Amsterdam and National Institute of Public Health and the Environment Amsterdam The Netherlands."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Noah N. and B. Henderson. 2002. Surveillance of bacterial meningitis in Europe 1999\/2000 abridged version. The European Bacterial Meningitis Surveillance Project PHLS Communicable Disease Surveillance Centre London United Kingdom. www.hpa.org.uk\/hpa\/inter\/m_surveillance9900.pdf\n.","DOI":"10.2807\/esw.06.15.02116-en"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2165\/00003495-199855030-00003","volume":"55","year":"1998","unstructured":"Peltola, H. 1998. Meningococcal vaccines. Current status and future possibilities. Drugs55:347-366.","journal-title":"Drugs"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1086\/376997","volume":"188","year":"2003","unstructured":"Ramsay, M. E., J. McVernon, N. J. Andrews, P. T. Heath, and M. P. Slack. 2003. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J. Infect. Dis.188:481-485.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1086\/314753","volume":"179","year":"1999","unstructured":"Richmond, P., R. Borrow, E. Miller, S. Clark, F. Sadler, A. Fox, N. Begg, R. Morris, and K. Cartwright. 1999. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J. Infect. Dis.179:1569-1572.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/317646","volume":"183","year":"2001","unstructured":"Richmond, P., R. Borrow, D. Goldblatt, J. Findlow, S. Martin, R. Morris, K. Cartwright, and E. Miller. 2001. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J. Infect. Dis.183:160-163.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","volume":"344","year":"2001","unstructured":"Rosenstein, N. E., B. A. Perkins, D. S. Stephens, T. Popovic, and J. M. Hughes. 2001. Meningococcal disease. N. Engl. J. Med.344:1378-1388.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s004310050797","volume":"157","year":"1998","unstructured":"Schmitt, H. J., F. Zepp, S. M\u00fcschenborn, G. Sumenicht, A. Schuind, K. Beutel, M. Knuf, H. L. Bock, H. Bogaerts, and R. Clemens. 1998. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and booster immunizations. Eur. J. Pediatr.157:208-214.","journal-title":"Eur. J. Pediatr."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.inf.0000151029.58752.27","volume":"24","year":"2005","unstructured":"Snape, M. D., D. F. Kelly, B. Green, E. R. Moxon, R. Borrow, and A. J. Pollard. 2005. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr. Infect. Dis. J.24:128-131.","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0140-6736(03)12441-5","volume":"361","year":"2003","unstructured":"Steinhoff, M., and D. Goldblatt. 2003. Conjugate Hib vaccines. Lancet361:360-361.","journal-title":"Lancet"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.inf.0000247070.60063.09","volume":"26","year":"2007","unstructured":"Tejedor, J. C., M. Moro, J. Ruiz-Contreras, J. Castro, J. A. G\u00f3mez-Campder\u00e1, M. L. Navarro, J. M. Merino, A. Martin-Ancel, J. Roca, M. Garcia-del-Ri, A. Jurado, F. J. Diez-Delgado, F. Omenaca, J. Garcia-Sicilia, R. Bocetas, P. Garcia-Corbeira, A. Collard, D. Boutriau, L. Schuerman, and J. M. Jacquet. 2007. Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae type b and Neisseria meningitidis coadministered with a diphtheria-tetanus-acellular pertusis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months. Pediatr. Infect. Dis. J.26:1-7.","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.inf.0000148923.46453.48","volume":"24","year":"2005","unstructured":"Tichmann-Schumann, I., P. Soemantri, U. Behre, J. Disselhoff, H. Mahler, G. Maechler, R. Sanger, J. M. Jacquet, and L. Schuerman. 2005. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J.24:70-77.","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","volume":"364","year":"2004","unstructured":"Trotter, C. L., N. J. Andrews, E. B. Kaczmarski, E. Miller, and M. E. Ramsay. 2004. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet364:365-367.","journal-title":"Lancet"},{"key":"e_1_3_2_25_2","first-page":"4","volume":"36","year":"2001","unstructured":"Van Loock, F., G. Ducoffre, and F. Carion. 2001. Meningokokkeninfecties: staan we voor een nieuwe epidemie? Epidemiol. Bull. Vlaamse Gemeenschap36:4-7.","journal-title":"Epidemiol. Bull. Vlaamse Gemeenschap"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00377-06","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00377-06","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:38:16Z","timestamp":1627591096000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00377-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["10.1128\/CVI.00377-06"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00377-06","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4]]},"assertion":[{"value":"2006-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-01-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}